Comparator group
[용어속성] Term
A role for human leucocyte antigens in the susceptibility to SARS‐Cov‐2 infection observed in transplant patients
Original Article
[키워드] 95% CI
analysed
Analysis
Antigen
association
case/control studies
Clinical management
Cohort
Comparator group
controls
Deceased
disease association
disease association studies
Donor
Frequency
genetics
histocompatibility
HLA
HLA frequency
human leucocyte antigens
immune response
immunology
individual
infected patients
Infection
information
Interaction
leucocyte
molecular
pandemic
Patient
Population
positive
protective effect
representing
RNA
SARS‐CoV‐2
Severe acute respiratory syndrome
Support
susceptibility
tested
Virology
virus
[DOI] 10.1111/iji.12505 PMC 바로가기 [Article Type] Original Article
[DOI] 10.1111/iji.12505 PMC 바로가기 [Article Type] Original Article
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Research article
[키워드] 95% CI
acute respiratory syndrome
Anticoagulants
Antigen
association
Asymptomatic
Benign
biochemical marker
Biomarker
CD40 ligand
clinical outcomes
Coagulation factors
Coagulopathy
Comparator group
complications
Concentration
Control
controls
coronavirus
correlated
correlation
COVID-19
Critical
cross-sectional
death
determine
elevated
Endothelial cell
endotheliopathy
Enzymes
Evidence
Factor
fibrinolytic
finding
funding
greater
hazard ratio
hematology
hospital
hospital discharge
hospitalised
ICU
ICU patient
ICU Patients
IMPROVE
Injury
intensive care
involved
Kaplan–Meier analysis
laboratory result
laboratory-confirmed
likelihood
marker
mitigate
Mortality
non-critically ill patient
non-hospitalised
non-ICU
non-ICU patients
outcome
P-selectin
Pathogenesis
Patient
patients
patients with COVID-19
platelet activation
previous study
progression
recruited
significantly
suggested
supported
survival
thrombotic
vWF
was used
with COVID-19
[DOI] 10.1016/S2352-3026(20)30216-7 [Article Type] Research article
[DOI] 10.1016/S2352-3026(20)30216-7 [Article Type] Research article
Should azithromycin be used to treat COVID-19? A rapid review
Research
[키워드] adverse event
Anti-bacterial agents
Anti-SARS-CoV-2 Activity
Azithromycin
Bacterial
clinical trial
clinical trials
Comparator group
conducted
COVID
COVID-19
drug
effective
Effectiveness
Evidence
for inclusion
General practice
Google
high risk
Hydroxychloroquine
in vitro
in vitro study
in vivo
include
Map
medRxiv
patients
patients with COVID-19
Primary Health Care
Result
SARS-CoV-2
Support
synergy
treat
treated
treating COVID-19
Treatment
treatments for COVID-19
Trial
viral clearance
while
[DOI] 10.3399/bjgpopen20X101094 PMC 바로가기 [Article Type] Research
[DOI] 10.3399/bjgpopen20X101094 PMC 바로가기 [Article Type] Research
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
95% CI
absence
addition
administration of hydroxychloroquine
Admission
aerosol-generating procedures
allergy
analyzed
Anesthesia
antibody
approved
ARMS
assigned
balanced randomization
blind
Cancer
Cantabria
carried
CDC
Cell
Chemoprophylaxis
clinical
Clinical data
clinically
coated
Committee
comparator
Comparator group
computer-generated
control group
Controlled
Controlled clinical trial
Controlled trial
coronavirus
COVID
COVID-19
criteria
CURB
current
detect
Determination
disease
dissemination
double blind
double-blind
dropout rate
Efficacy
Efficacy and safety
element
ELISA kit
Emergency
Endocrine
estimate
Ethics
Euroimmun
Evidence
evidence of
Germany
GRADE
greater
group
Health
Health authority
health-care
healthcare personnel
Healthcare professional
healthcare professionals
heart
heart failure
help
hematological
high risk
hospital
Hydroxychloroquine
hydroxychloroquine sulfate
hygiene
Hypothesis
ICU
IDT
IgA
IgG
IgM and IgG
immune
immunodeficiency
in vitro
incidence
include
Infection
inhibit
intensive care unit
Intervention
investigator
kidney
lactation
liver
measure
Measures
Medicine
Negative PCR
neurological
New York
number
observation period
outcome
participant
PCR
performed
Personal protective equipment
Placebo
positive
positive SARS-CoV-2 PCR
positive serology
Pregnancy
presenting
Prevalence
Primary outcome
probes
product
professional
Prophylaxis
Prospective
PROTECT
Protective
protocol
Psychiatric
randomised
randomised controlled trial
randomization
Randomized
randomized trial
RCT
receive
recruitment
reduce
reported
responsible
risk
RT-PCR
Sample size
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 PCR
sequence
Seroconversion
serological
serology
severity
Significant
single center
single-center study
social distancing
Spain
Spanish
Standard
Statistical power
status
Study protocol
subject
Support
Symptom
symptomatic and asymptomatic
Tablet
Takara
Taking
Tamoxifen
Transmission
Treatment
two-tailed
university
Vaccine
virus
website
while
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter